The market for glucagon-like peptide-1 (GLP-1) agonists has seen tremendous development and transition, driven by a variety of factors that affect its direction
Common side effects unique to semaglutide (Wegovy) include bloating, belching, flatulence, heartburn, and the common cold
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - Oral Formulations and Long-Acting Peptides Accelerate Next-Gen Obesity and Diabetes Therapies The glucagon-like peptide 1 (GLP-1) market is poised for growth due to rising diabetes and obesity rates, expanded therapy options, and a focus on personalized medicine
Even if GLP-1 monotherapy is found to be less effective for opioid cessation than a combination therapy, it has the potential to reach vastly more patients and reach them at earlier stages, including the high percentage of patients who have refused existing medication options
If a schedule change is needed, it should be done only under a doctor's guidance
Campbell Live, TV3
